USPTO serial 79290127
NOAELTAXEL
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- —
- Examiner
- SEVERSON, JUSTIN
- Law office
- TMO LAW OFFICE 111 - EXAMINING ATTORNEY ASSIGNED
What this means
These status codes mean the trademark application is abandoned and no longer pending. Common reasons include missing an Office Action response (600), filing without a valid basis (602), express abandonment by the applicant (604), or failure to respond to an examiner's inquiry (618). Revival may be possible in limited circumstances. If abandonment was unintentional, consult counsel about a petition to revive. Otherwise file a new application if protection is still needed.
Need help with NOAELTAXEL?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Medicines for the treatment of gastrointestinal diseases; injectable mineral solutions for medical purposes; antioxidants for medical purposes; haematogen; pharmaceutical preparations for tumor treatment; multivitamin preparations; suppositories; pharmaceutical preparations acting on the central nervous system; pharmaceutical preparations for diagnosis; sedatives; analgesics; vaginal washes for medical purposes; pharmaceutical preparations for treating asthma; medicines for dental purposes; haemorrhoid preparations; pharmaceutical preparations for inhalation for the treatment of pulmonary hypertension; vaccines against pneumococcal infections; dermatological pharmaceutical products; contraceptive preparations; antihypertensives; anti-uric preparations; anti-diabetic pharmaceuticals; pharmaceutical preparations for anus; antibiotic preparations; antibiotics; anti-cancer preparations; anti-cancer treatment supplements; antidepressants; anticoagulants; antineoplastics; anti-dermoinfectives; antidotes; antipyretic analgesics; febrifuges; vasoconstrictors; hypoglycemic agents; blood thinners; pharmaceutical preparations for respiratory organs; respiratory stimulants; Pharmaceutical preparations; pharmaceutical agents affecting sensory organs; thyroid and para-thyroid hormone preparations; tonics [medicines]; oral contraceptive pills; antiemetics; local anesthetics; bronchodilating preparations; anti-cough drops; androgen preparations; pituitary hormone preparations; pharmaceutical preparations for treating diabetes; pharmaceutical agents affecting metabolism; vaccines against flu; chilblain preparations; pharmaceutical preparations for headache; anaesthetics; pharmaceutical agents affecting peripheral nervous system; pharmaceutical preparations for immunity adjustment; nutritive substances for microorganisms; pharmaceutical for the treatment of erectile dysfunction; pharmaceutical preparations for urogenital organs; vitamin preparations; pharmaceutical products for the treatment of bone diseases; anti-inflammatory and antipyretic preparations; pharmaceutical agents affecting digestive organs; cardiovascular pharmaceutical preparations; nervines; ophthalmic preparations; allergy medications; chemico-pharmaceutical preparations; inhaled pharmaceutical preparations for the treatment of respiratory diseases and disorders; pharmaceutical products for treating respiratory diseases and asthma; mixed vitamin preparations; preparations for the treatment of burns; disinfectants for chemical toilets; chemotherapeutics; preparations for treatment of hepatitis; preparations for treating colds; preparations for the treatment of hyperlipidemia; preparations for the treatment of hypercholesteremia; pharmaceutical preparations for treating hypertension; pharmaceutical preparations for the treatment of osteoporosis; preparations for the treatment of osteoporosis; injectable pharmaceuticals for treatment of anaphylactic reactions; pharmaceutical preparations for treating halitosis; nausea treatment preparations; antiulcerants; pharmaceutical preparations for the treatment of musculoskeletal disorders; preparations for the treatment of muscle fatigue; pharmaceutical preparations for treating chloasma; pharmaceutical preparations for the treatment of diseases of the endocrine system; pharmaceutical preparations for the treatment of eye diseases and conditions; pharmaceutical preparations for treating metabolic disorders; pharmaceutical preparations for treating peripheral nervous system disorders; pharmaceutical preparations for the treatment of dandruff; pharmaceutical preparations for the treatment of rhinitis; radioactive pharmaceutical preparations for in vivo diagnostics or therapeutic use; pharmaceutical preparations for the treatment of cells; medicines for treating intestinal disorders; cardiovascular treatment preparations; pharmaceutical preparations for the treatment of kidney diseases; pharmaceutical preparations for the treatment of disorders of the metabolic system; pharmaceutical preparations for treating allergies; pharmaceutical preparations and compositions for the treatment and prevention of cancer; biopharmaceuticals for the treatment of cancer; pharmaceutical products for the treatment of cancer; pharmaceutical preparations for the treatment of inflammatory disorders; pharmaceutical preparations and substances for the treatment of gastro-intestinal diseases; medicated mouth treatment preparations; transdermal patches for medical treatment; pharmaceutical preparations for the treatment of gout; drug delivery agents; drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceuticals; drug delivery agents in the form of powders that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of tablets that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents in the form of capsules that provide controlled release of the active ingredients for a wide variety of pharmaceuticals; drug delivery agents that facilitate the delivery of pharmaceutical preparations; drug delivery agents in the form of dissolvable films that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of dissolvable films that facilitate the delivery of nutritional supplements; drug delivery agents in the form of coatings for tablets that facilitate the delivery of pharmaceutical preparations; delivery agents in the form of coatings for tablets that facilitate the delivery of nutritional supplements | SECTION 70 - CANCELLED | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| May 30, 2022 | FINT | FINAL DECISION TRANSACTION PROCESSED BY IB | — |
| May 4, 2022 | FICS | FINAL DISPOSITION NOTICE SENT TO IB | — |
| May 4, 2022 | FICR | FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB | — |
| Mar 27, 2022 | DENA | NOTIFICATION OF EFFECT OF CANCELLATION OF INTL REG MAILED | — |
| Mar 26, 2022 | DETH | DEATH OF INTERNATIONAL REGISTRATION | — |
| Jan 15, 2022 | OPNX | NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB | — |
| Dec 29, 2021 | OPNS | NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB | — |
| Dec 29, 2021 | OPNR | NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB | — |
| Sep 3, 2021 | NREP | NEW REPRESENTATIVE AT IB RECEIVED | — |
| May 4, 2021 | MAB2 | ABANDONMENT NOTICE MAILED - FAILURE TO RESPOND | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| May 4, 2021 | ABN2 | ABANDONMENT - FAILURE TO RESPOND OR LATE RESPONSE | The trademark application was abandoned because a required response or document was not filed by the deadline — usually a missed Office Action response. The application is dead unless a petition to revive is granted within a limited time. |
| Nov 8, 2020 | RFNT | REFUSAL PROCESSED BY IB | — |
| Oct 19, 2020 | RFCS | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB | — |
| Oct 19, 2020 | RFRR | REFUSAL PROCESSED BY MPU | — |
| Sep 24, 2020 | RFCR | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW | — |
| Sep 23, 2020 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Sep 18, 2020 | DOCK | ASSIGNED TO EXAMINER | — |
| Jul 28, 2020 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Jul 24, 2020 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 23, 2020 | REPR | SN ASSIGNED FOR SECT 66A APPL FROM IB | — |